e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Assessment of severity and predictors of outcomes in community-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Relationship between the presence of hypoxemia and the inflammatory response measured by C-reactive protein in bacteremic pneumococcal pneumonia
F. Sanz, C. Gimeno, T. Lloret, N. Tormo, M. Briones, E. Fernández, A. Cervera, M. C. Aguar, E. Chiner, J. Blanquer (Valencia, Alacant, Spain)
Source:
Annual Congress 2011 - Assessment of severity and predictors of outcomes in community-acquired pneumonia
Session:
Assessment of severity and predictors of outcomes in community-acquired pneumonia
Session type:
Thematic Poster Session
Number:
2492
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Sanz, C. Gimeno, T. Lloret, N. Tormo, M. Briones, E. Fernández, A. Cervera, M. C. Aguar, E. Chiner, J. Blanquer (Valencia, Alacant, Spain). Relationship between the presence of hypoxemia and the inflammatory response measured by C-reactive protein in bacteremic pneumococcal pneumonia. Eur Respir J 2011; 38: Suppl. 55, 2492
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP)
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
C-reactive protein in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005
Effect of corticoids on the inflammatory response measured in blood in severe community-acquired pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 461s
Year: 2003
Measurements usefulness of serum C-reactive protein for management of adult community-acquired pneumonia
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia
Source: Eur Respir J 2010; 35: 805-811
Year: 2010
Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia
Source: Eur Respir J 2005; 25: 688-692
Year: 2005
High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012
Influence of the infecting serotype on the development of complications in bacteriemic pneumococcal pneumonia with high inflammatory response
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Measurement of procalcitonin levels in children with bacterial or viral acquired pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 191s
Year: 2002
C-reactive protein levels in community-acquired pneumonia
Source: Eur Respir J 2003; 21: 702-705
Year: 2003
Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia
Source: Eur Respir J 2008; 32: 726-732
Year: 2008
Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006
Systemic cytokine levels in community-acquired pneumonia and their association with disease severity
Source: Eur Respir J 2002; 20: 990-995
Year: 2002
The clinical significance of serum and bronchoalveoalr lavage inflammatory cytokine in patients with acute respiratory failure due to severe community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 347s
Year: 2006
Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function
Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Year: 2008
Comparison of inflammatory response biomarkers to predict complications in hospitalized patients with community-acquired pneumonia
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Combined serum eosinophil count and procalcitonin level as a marker of bacterial infection in acute exacerbation of chronic obstructive pulmonary disease
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept